1
|
Alhattab M, Moorthy LS, Patel D, Franco CMM, Puri M. Oleaginous Microbial Lipids' Potential in the Prevention and Treatment of Neurological Disorders. Mar Drugs 2024; 22:80. [PMID: 38393051 PMCID: PMC10890163 DOI: 10.3390/md22020080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2023] [Revised: 01/30/2024] [Accepted: 02/02/2024] [Indexed: 02/25/2024] Open
Abstract
The products of oleaginous microbes, primarily lipids, have gained tremendous attention for their health benefits in food-based applications as supplements. However, this emerging biotechnology also offers a neuroprotective treatment/management potential for various diseases that are seldom discussed. Essential fatty acids, such as DHA, are known to make up the majority of brain phospholipid membranes and are integral to cognitive function, which forms an important defense against Alzheimer's disease. Omega-3 polyunsaturated fatty acids have also been shown to reduce recurrent epilepsy seizures and have been used in brain cancer therapies. The ratio of omega-3 to omega-6 PUFAs is essential in maintaining physiological function. Furthermore, lipids have also been employed as an effective vehicle to deliver drugs for the treatment of diseases. Lipid nanoparticle technology, used in pharmaceuticals and cosmeceuticals, has recently emerged as a biocompatible, biodegradable, low-toxicity, and high-stability means for drug delivery to address the drawbacks associated with traditional medicine delivery methods. This review aims to highlight the dual benefit that lipids offer in maintaining good health for disease prevention and in the treatment of neurological diseases.
Collapse
Affiliation(s)
- Mariam Alhattab
- Medical Biotechnology, College of Medicine and Public Health, Flinders University, Bedford Park, Adelaide 5042, Australia
| | - Lakshana S Moorthy
- Medical Biotechnology, College of Medicine and Public Health, Flinders University, Bedford Park, Adelaide 5042, Australia
| | - Durva Patel
- Medical Biotechnology, College of Medicine and Public Health, Flinders University, Bedford Park, Adelaide 5042, Australia
| | - Christopher M M Franco
- Medical Biotechnology, College of Medicine and Public Health, Flinders University, Bedford Park, Adelaide 5042, Australia
- Flinders Health and Medical Research Institute, Flinders University, Adelaide 5042, Australia
| | - Munish Puri
- Medical Biotechnology, College of Medicine and Public Health, Flinders University, Bedford Park, Adelaide 5042, Australia
- Flinders Health and Medical Research Institute, Flinders University, Adelaide 5042, Australia
| |
Collapse
|
2
|
Djite M, Chao de la Barca JM, Bocca C, Gaye NM, Barry NOK, Mbacke MN, Cissé O, Kandji PM, Thioune NM, Coly-Gueye NF, Ndour EHM, Gueye-Tall F, Diop AG, Simard G, Mirebeau-Prunier D, Gueye PM, Reynier P. A Metabolomic Signature of Ischemic Stroke Showing Acute Oxidative and Energetic Stress. Antioxidants (Basel) 2023; 13:60. [PMID: 38247484 PMCID: PMC10812657 DOI: 10.3390/antiox13010060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2023] [Revised: 11/28/2023] [Accepted: 12/25/2023] [Indexed: 01/23/2024] Open
Abstract
Metabolomics is a powerful data-driven tool for in-depth biological phenotyping that could help identify the specific metabolic profile of cryptogenic strokes, for which no precise cause has been identified. We performed a targeted quantitative metabolomics study in West African patients who had recently suffered an ischemic stroke, which was either cryptogenic (n = 40) or had a clearly identified cause (n = 39), compared to a healthy control group (n = 40). Four hundred fifty-six metabolites were accurately measured. Multivariate analyses failed to reveal any metabolic profile discriminating between cryptogenic ischemic strokes and those with an identified cause but did show superimposable metabolic profiles in both groups, which were clearly distinct from those of healthy controls. The blood concentrations of 234 metabolites were significantly affected in stroke patients compared to controls after the Benjamini-Hochberg correction. Increased methionine sulfoxide and homocysteine concentrations, as well as an overall increase in saturation of fatty acids, were indicative of acute oxidative stress. This signature also showed alterations in energetic metabolism, cell membrane integrity, monocarbon metabolism, and neurotransmission, with reduced concentrations of several metabolites known to be neuroprotective. Overall, our results show that cryptogenic strokes are not pathophysiologically distinct from ischemic strokes of established origin, and that stroke leads to intense metabolic remodeling with marked oxidative and energetic stresses.
Collapse
Affiliation(s)
- Moustapha Djite
- Laboratoire de Biochimie Pharmaceutique, Faculté de Médecine, Pharmacie, Université Cheikh Anta Diop, Dakar 2238, Senegal; (N.O.K.B.); (E.H.M.N.); (F.G.-T.); (P.M.G.)
- Laboratoire de Biochimie, Centre Hospitalier National Universitaire (CHNU) de FANN, Dakar 45701, Senegal; (M.N.M.); (P.M.K.); (N.M.T.)
| | - Juan Manuel Chao de la Barca
- Département de Biochimie et Biologie Moléculaire, Centre Hospitalier Universitaire (CHU), 49933 Angers, France; (J.M.C.d.l.B.); (C.B.); (G.S.); (D.M.-P.); (P.R.)
- Unité Mixte de Recherche (UMR) MITOVASC, Institut National de la Santé et de la Recherche Médicale (INSERM U-1083), Centre National de la Recherche Scientifique (CNRS 6015), Université d’Angers, 49933 Angers, France
| | - Cinzia Bocca
- Département de Biochimie et Biologie Moléculaire, Centre Hospitalier Universitaire (CHU), 49933 Angers, France; (J.M.C.d.l.B.); (C.B.); (G.S.); (D.M.-P.); (P.R.)
- Unité Mixte de Recherche (UMR) MITOVASC, Institut National de la Santé et de la Recherche Médicale (INSERM U-1083), Centre National de la Recherche Scientifique (CNRS 6015), Université d’Angers, 49933 Angers, France
| | - Ndiaga Matar Gaye
- Clinique Neurologique, Centre Hospitalier National Universitaire (CHNU) de FANN, Dakar 45701, Senegal; (N.M.G.); (O.C.); (A.G.D.)
| | - Néné Oumou Kesso Barry
- Laboratoire de Biochimie Pharmaceutique, Faculté de Médecine, Pharmacie, Université Cheikh Anta Diop, Dakar 2238, Senegal; (N.O.K.B.); (E.H.M.N.); (F.G.-T.); (P.M.G.)
- Laboratoire de Biochimie, Centre Hospitalier National Universitaire (CHNU) de FANN, Dakar 45701, Senegal; (M.N.M.); (P.M.K.); (N.M.T.)
| | - Mame Ndoumbé Mbacke
- Laboratoire de Biochimie, Centre Hospitalier National Universitaire (CHNU) de FANN, Dakar 45701, Senegal; (M.N.M.); (P.M.K.); (N.M.T.)
| | - Ousmane Cissé
- Clinique Neurologique, Centre Hospitalier National Universitaire (CHNU) de FANN, Dakar 45701, Senegal; (N.M.G.); (O.C.); (A.G.D.)
| | - Pape Matar Kandji
- Laboratoire de Biochimie, Centre Hospitalier National Universitaire (CHNU) de FANN, Dakar 45701, Senegal; (M.N.M.); (P.M.K.); (N.M.T.)
| | - Ndèye Marème Thioune
- Laboratoire de Biochimie, Centre Hospitalier National Universitaire (CHNU) de FANN, Dakar 45701, Senegal; (M.N.M.); (P.M.K.); (N.M.T.)
| | | | - El Hadji Malick Ndour
- Laboratoire de Biochimie Pharmaceutique, Faculté de Médecine, Pharmacie, Université Cheikh Anta Diop, Dakar 2238, Senegal; (N.O.K.B.); (E.H.M.N.); (F.G.-T.); (P.M.G.)
| | - Fatou Gueye-Tall
- Laboratoire de Biochimie Pharmaceutique, Faculté de Médecine, Pharmacie, Université Cheikh Anta Diop, Dakar 2238, Senegal; (N.O.K.B.); (E.H.M.N.); (F.G.-T.); (P.M.G.)
| | - Amadou Gallo Diop
- Clinique Neurologique, Centre Hospitalier National Universitaire (CHNU) de FANN, Dakar 45701, Senegal; (N.M.G.); (O.C.); (A.G.D.)
| | - Gilles Simard
- Département de Biochimie et Biologie Moléculaire, Centre Hospitalier Universitaire (CHU), 49933 Angers, France; (J.M.C.d.l.B.); (C.B.); (G.S.); (D.M.-P.); (P.R.)
| | - Delphine Mirebeau-Prunier
- Département de Biochimie et Biologie Moléculaire, Centre Hospitalier Universitaire (CHU), 49933 Angers, France; (J.M.C.d.l.B.); (C.B.); (G.S.); (D.M.-P.); (P.R.)
- Unité Mixte de Recherche (UMR) MITOVASC, Institut National de la Santé et de la Recherche Médicale (INSERM U-1083), Centre National de la Recherche Scientifique (CNRS 6015), Université d’Angers, 49933 Angers, France
| | - Papa Madieye Gueye
- Laboratoire de Biochimie Pharmaceutique, Faculté de Médecine, Pharmacie, Université Cheikh Anta Diop, Dakar 2238, Senegal; (N.O.K.B.); (E.H.M.N.); (F.G.-T.); (P.M.G.)
- Laboratoire de Biochimie, Centre Hospitalier National Universitaire (CHNU) de FANN, Dakar 45701, Senegal; (M.N.M.); (P.M.K.); (N.M.T.)
| | - Pascal Reynier
- Département de Biochimie et Biologie Moléculaire, Centre Hospitalier Universitaire (CHU), 49933 Angers, France; (J.M.C.d.l.B.); (C.B.); (G.S.); (D.M.-P.); (P.R.)
- Unité Mixte de Recherche (UMR) MITOVASC, Institut National de la Santé et de la Recherche Médicale (INSERM U-1083), Centre National de la Recherche Scientifique (CNRS 6015), Université d’Angers, 49933 Angers, France
| |
Collapse
|
3
|
Ma J, Kitaura H, Ohori F, Noguchi T, Marahleh A, Kinjo R, Kanou K, Ren J, Miura M, Narita K, Mizoguchi I. Generating Bone Marrow Chimeric Mouse Using GPR120 Deficient Mouse for the Study of DHA Inhibitory Effect on Osteoclast Formation and Bone Resorption. Int J Mol Sci 2023; 24:17000. [PMID: 38069322 PMCID: PMC10707107 DOI: 10.3390/ijms242317000] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2023] [Revised: 11/22/2023] [Accepted: 11/29/2023] [Indexed: 12/18/2023] Open
Abstract
Docosahexaenoic acid (DHA) is an omega-3 fatty acid that exerts physiological effects via G protein-coupled receptor 120 (GPR120). In our previous studies, we figured out the inhibitory effects of DHA on TNF-α (Tumor necrosis factor-α)-induced osteoclastogenesis via GPR120 in vivo. Moreover, DHA directly suppressed RANKL expression in osteoblasts via GPR120 in vitro. In this study, we generated bone marrow chimeric mice using GPR120 deficient mice (GPR120-KO) to study the inhibitory effects of DHA on bone resorption and osteoclast formation. Bone marrow cells of wild-type (WT) or GPR120-KO mice were transplanted into irradiated recipient mice, which were WT or GPR120 deficient mice. The resulting chimeric mice contained stromal cells from the recipient and bone marrow cells, including osteoclast precursors, from the donor. These chimeric mice were used to perform a series of histological and microfocus computed tomography (micro-CT) analyses after TNF-α injection for induction of osteoclast formation with or without DHA. Osteoclast number and bone resorption were found to be significantly increased in chimeric mice, which did not express GPR120 in stromal cells, compared to chimeric mice, which expressed GPR120 in stromal cells. DHA was also found to suppress specific signaling pathways. We summarized that DHA suppressed TNF-α-induced stromal-dependent osteoclast formation and bone resorption via GPR120.
Collapse
Affiliation(s)
- Jinghan Ma
- Division of Orthodontics and Dentofacial Orthopedics, Tohoku University Graduate School of Dentistry, 4-1, Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan; (J.M.); (F.O.); (T.N.); (R.K.); (K.K.); (J.R.); (M.M.); (K.N.); (I.M.)
| | - Hideki Kitaura
- Division of Orthodontics and Dentofacial Orthopedics, Tohoku University Graduate School of Dentistry, 4-1, Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan; (J.M.); (F.O.); (T.N.); (R.K.); (K.K.); (J.R.); (M.M.); (K.N.); (I.M.)
| | - Fumitoshi Ohori
- Division of Orthodontics and Dentofacial Orthopedics, Tohoku University Graduate School of Dentistry, 4-1, Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan; (J.M.); (F.O.); (T.N.); (R.K.); (K.K.); (J.R.); (M.M.); (K.N.); (I.M.)
| | - Takahiro Noguchi
- Division of Orthodontics and Dentofacial Orthopedics, Tohoku University Graduate School of Dentistry, 4-1, Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan; (J.M.); (F.O.); (T.N.); (R.K.); (K.K.); (J.R.); (M.M.); (K.N.); (I.M.)
| | - Aseel Marahleh
- Frontier Research Institute for Interdisciplinary Sciences, Tohoku University, Sendai 980-8575, Japan;
| | - Ria Kinjo
- Division of Orthodontics and Dentofacial Orthopedics, Tohoku University Graduate School of Dentistry, 4-1, Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan; (J.M.); (F.O.); (T.N.); (R.K.); (K.K.); (J.R.); (M.M.); (K.N.); (I.M.)
| | - Kayoko Kanou
- Division of Orthodontics and Dentofacial Orthopedics, Tohoku University Graduate School of Dentistry, 4-1, Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan; (J.M.); (F.O.); (T.N.); (R.K.); (K.K.); (J.R.); (M.M.); (K.N.); (I.M.)
| | - Jiayi Ren
- Division of Orthodontics and Dentofacial Orthopedics, Tohoku University Graduate School of Dentistry, 4-1, Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan; (J.M.); (F.O.); (T.N.); (R.K.); (K.K.); (J.R.); (M.M.); (K.N.); (I.M.)
| | - Mariko Miura
- Division of Orthodontics and Dentofacial Orthopedics, Tohoku University Graduate School of Dentistry, 4-1, Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan; (J.M.); (F.O.); (T.N.); (R.K.); (K.K.); (J.R.); (M.M.); (K.N.); (I.M.)
| | - Kohei Narita
- Division of Orthodontics and Dentofacial Orthopedics, Tohoku University Graduate School of Dentistry, 4-1, Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan; (J.M.); (F.O.); (T.N.); (R.K.); (K.K.); (J.R.); (M.M.); (K.N.); (I.M.)
| | - Itaru Mizoguchi
- Division of Orthodontics and Dentofacial Orthopedics, Tohoku University Graduate School of Dentistry, 4-1, Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan; (J.M.); (F.O.); (T.N.); (R.K.); (K.K.); (J.R.); (M.M.); (K.N.); (I.M.)
| |
Collapse
|